Amit Khatri1, Sandeep Dutta2, Thomas C Marbury3, Richard A Preston4, Lino Rodrigues5, Haoyu Wang6, Walid M Awni2, Rajeev M Menon2. 1. Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Dept. R4PK, Bldg. AP-31-3, 1 North Waukegan Rd, North Chicago, IL, 60064, USA. amit.khatri@abbvie.com. 2. Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Dept. R4PK, Bldg. AP-31-3, 1 North Waukegan Rd, North Chicago, IL, 60064, USA. 3. Clinical Research, Orlando Clinical Research Center, Orlando, FL, USA. 4. Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USA. 5. Antiviral Global Project Team, AbbVie Inc., North Chicago, IL, USA. 6. Biometrics, AbbVie Inc., North Chicago, IL, USA.
Abstract
BACKGROUND: The direct-acting antiviral agent (DAA) combination of ombitasvir and paritaprevir (administered with ritonavir) with (3D regimen) or without (2D regimen) dasabuvir has shown very high efficacy rates in the treatment of chronic hepatitis C virus (HCV) infection. Renal impairment, a common comorbidity in patients with chronic HCV infection, can influence the pharmacokinetics of antiviral agents and hence their efficacy and safety profiles. OBJECTIVE: The aim of this study was to evaluate the influence of renal impairment on the pharmacokinetics and tolerability of the 3D and 2D regimens. METHODS: Overall, 24 subjects, six in each of four renal function groups (normal, mild, moderate, and severe), received a single dose of the 3D and 2D regimens in separate dosing periods. Plasma and urine were analyzed to assess the effect of renal impairment on drug exposure. RESULTS: DAA exposures changed by up to 21, 37, and 50 % in subjects with mild, moderate, and severe renal impairment, respectively, versus subjects with normal renal function. Ritonavir exposure increased with the degree of renal impairment (maximum 114 %). The half-lives of DAAs and ritonavir in subjects with renal impairment were generally comparable with those in healthy subjects. No safety or tolerability concerns arose in this study. CONCLUSION: The 3D and 2D regimens do not require dose adjustment for patients with HCV infection and concomitant renal impairment.
BACKGROUND: The direct-acting antiviral agent (DAA) combination of ombitasvir and paritaprevir (administered with ritonavir) with (3D regimen) or without (2D regimen) dasabuvir has shown very high efficacy rates in the treatment of chronic hepatitis C virus (HCV) infection. Renal impairment, a common comorbidity in patients with chronic HCV infection, can influence the pharmacokinetics of antiviral agents and hence their efficacy and safety profiles. OBJECTIVE: The aim of this study was to evaluate the influence of renal impairment on the pharmacokinetics and tolerability of the 3D and 2D regimens. METHODS: Overall, 24 subjects, six in each of four renal function groups (normal, mild, moderate, and severe), received a single dose of the 3D and 2D regimens in separate dosing periods. Plasma and urine were analyzed to assess the effect of renal impairment on drug exposure. RESULTS:DAA exposures changed by up to 21, 37, and 50 % in subjects with mild, moderate, and severe renal impairment, respectively, versus subjects with normal renal function. Ritonavir exposure increased with the degree of renal impairment (maximum 114 %). The half-lives of DAAs and ritonavir in subjects with renal impairment were generally comparable with those in healthy subjects. No safety or tolerability concerns arose in this study. CONCLUSION: The 3D and 2D regimens do not require dose adjustment for patients with HCV infection and concomitant renal impairment.
Authors: Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy Journal: N Engl J Med Date: 2014-05-04 Impact factor: 91.245
Authors: Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245
Authors: Akshanth R Polepally; Sandeep Dutta; Beibei Hu; Thomas J Podsadecki; Walid M Awni; Rajeev M Menon Journal: Clin Pharmacol Drug Dev Date: 2016-01-24
Authors: Tushar Garimella; Reena Wang; Wen-Lin Luo; Carey Hwang; Diane Sherman; Hamza Kandoussi; Thomas C Marbury; Harry Alcorn; Richard Bertz; Marc Bifano Journal: Antivir Ther Date: 2015-02-05
Authors: Fred Poordad; Eric Lawitz; Kris V Kowdley; Daniel E Cohen; Thomas Podsadecki; Sara Siggelkow; Michele Heckaman; Lois Larsen; Rajeev Menon; Gennadiy Koev; Rakesh Tripathi; Tami Pilot-Matias; Barry Bernstein Journal: N Engl J Med Date: 2013-01-03 Impact factor: 91.245
Authors: Clara T M M de Kanter; Joost P H Drenth; Joop E Arends; Henk W Reesink; Marc van der Valk; Robert J de Knegt; David M Burger Journal: Clin Pharmacokinet Date: 2014-05 Impact factor: 5.577
Authors: Eric Lawitz; Edward Gane; Eric Cohen; John Vierling; Kosh Agarwal; Tarek Hassanein; Parvez S Mantry; Paul J Pockros; Michael Bennett; Nyingi Kemmer; Giuseppe Morelli; Jiuhong Zha; Deli Wang; Nancy S Shulman; Daniel E Cohen; K Rajender Reddy Journal: Kidney Int Rep Date: 2018-10-09